目次

Table of Content

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Service
1.1.2. End use
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4

Chapter 2. Executive Summary
2.1. Market Outlook

Chapter 3. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.2.2.1. Quality issues associated with outsourcing
3.2.3. Covid-19 Impact & Recovery Analysis
3.2.4. Industry Analysis - Porter’s
3.2.5. PESTLE Analysis

Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Application Segment Analysis
4.1. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Market : Definition & Scope
4.2. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Market : Service Market Share Analysis, 2022 & 2030
4.2.1. C.difficle
4.2.1.1. C.difficle market, 2018 - 2030 (USD Million)
4.2.1.2. Crohns disease
4.2.1.2.1. Crohns disease market, 2018 - 2030 (USD Million)
4.2.1.3. IBS
4.2.1.3.1. IBS market, 2018 - 2030 (USD Million)
4.2.1.4. Diabetes
4.2.1.4.1. Diabetes market, 2018 - 2030 (USD Million)
4.2.1.5. Others
4.2.1.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Regional Analysis
5.1. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Regional market share analysis, 2022 & 2030
5.2. North America
5.2.1. North America Market estimates and forecast, 2018 - 2030
5.2.2. U.S.
5.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
5.2.3. Canada
5.2.3.1. Canada Market estimates and forecast, 2018 - 2030
5.3. Europe
5.3.1. Europe Market estimates and forecast, 2018 - 2030
5.3.2. UK
5.3.2.1. UK Market estimates and forecast, 2018 - 2030
5.3.3. Germany
5.3.3.1. Germany Market estimates and forecast, 2018 - 2030
5.3.4. France
5.3.4.1. France Market estimates and forecast, 2018 - 2030
5.3.5. Italy
5.3.5.1. Italy Market estimates and forecast, 2018 - 2030
5.3.6. Spain
5.3.6.1. Spain Market estimates and forecast, 2018 - 2030
5.3.7. Denmark
5.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
5.3.8. Sweden
5.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
5.3.9. Norway
5.3.9.1. Norway Market estimates and forecast, 2018 - 2030
5.4. Asia Pacific
5.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
5.4.2. Japan
5.4.2.1. Japan Market estimates and forecast, 2018 - 2030
5.4.3. China
5.4.3.1. China Market estimates and forecast, 2018 - 2030
5.4.4. India
5.4.4.1. India Market estimates and forecast, 2018 - 2030
5.4.5. South Korea
5.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
5.4.6. Australia
5.4.6.1. Australia Market estimates and forecast, 2018 - 2030
5.4.7. Thailand
5.4.7.1. Thailand Market estimates and forecast, 2018 - 2030
5.5. Latin America
5.5.1. Latin America Market estimates and forecast, 2018 - 2030
5.5.2. Brazil
5.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
5.5.3. Mexico
5.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
5.5.4. Argentina
5.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
5.6. `MEA
5.6.1. MEA Market estimates and forecast, 2018 - 2030
5.6.2. South Africa
5.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
5.6.3. Saudi Arabia
5.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
5.6.4. UAE
5.6.4.1. UAE Market estimates and forecast, 2018 - 2030
5.6.5. Kuwait
5.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030

Chapter 6. Competitive Landscape
6.1. Arrant Bio
6.1.1. Company overview
6.1.2. Financial performance
6.1.3. Service benchmarking
6.1.4. Strategic initiatives
6.2. 4D Pharma
6.2.1. Company overview
6.2.2. Financial performance
6.2.3. Service benchmarking
6.2.4. Strategic initiatives
6.3. Cerbios
6.3.1. Company overview
6.3.2. Financial performance
6.3.3. Service benchmarking
6.3.4. Strategic initiatives
6.4. Biose Industrie
6.4.1. Company overview
6.4.2. Financial performance
6.4.3. Service benchmarking
6.4.4. Strategic initiatives
6.5. Assembly Biosciences, Inc
6.5.1. Company overview
6.5.2. Financial performance
6.5.3. Service benchmarking
6.5.4. Strategic initiatives
6.6. Wacker Chemie AG
6.6.1. Company overview
6.6.2. Financial performance
6.6.3. Service benchmarking
6.6.4. Strategic initiatives
6.7. Quay Pharmaceuticals
6.7.1. Company overview
6.7.2. Financial performance
6.7.3. Service benchmarking
6.7.4. Strategic initiatives
6.8. NIZO
6.8.1. Company overview
6.8.2. Financial performance
6.8.3. Service benchmarking
6.8.4. Strategic initiatives
6.9. LONZA
6.9.1. Company overview
6.9.2. Financial performance
6.9.3. Service benchmarking
6.9.4. Strategic initiatives
6.10. Inpac Probiotics
6.10.1. Company overview
6.10.2. Financial performance
6.10.3. Service benchmarking
6.10.4. Strategic initiatives

List of Tables
TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations

List of Figures
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market segmentation & scope
FIG. 8 Live Biotherapeutic Products and Microbiome CDMO outlook, 2018 - 2030
FIG. 9 Market trends & outlook
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 Live Biotherapeutic Products and Microbiome CDMO : Application outlook key takeaways
FIG. 15 Live Biotherapeutic Products and Microbiome CDMO : Application movement analysis
FIG. 16 C.difficle market, 2018 - 2030 (USD Million)
FIG. 17 Crohns disease market, 2018 - 2030 (USD Million)
FIG. 18 IBS market, 2018 - 2030 (USD Million)
FIG. 19 Diabetes market, 2018 - 2030 (USD Million)
FIG. 20 Others market, 2018 - 2030 (USD Million)
FIG. 21 Regional market place: Key takeaway
FIG. 22 Live Biotherapeutic Products and Microbiome CDMO regional outlook, 2020 & 2028
FIG. 23 North America Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 24 U.S. Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 25 Canada Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 26 Europe Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 27 Germany Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 28 France Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 29 UK Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 30 Spain Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 31 Italy Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 32 Denmark Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 33 Sweden Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 34 Norway Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 35 Asia Pacific Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 36 China Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 37 Japan Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 38 India Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 39 Thailand Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 40 South Korea Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 41 Australia Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 42 Latin America Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 43 Brazil Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 44 Mexico Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 45 Argentina Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 46 Middle East & Africa Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 47 South Africa Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 48 Saudi Arabia Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 49 UAE Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
FIG. 50 Kuwait Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)